vs
Side-by-side financial comparison of Boston Scientific (BSX) and PILGRIMS PRIDE CORP (PPC). Click either name above to swap in a different company.
Boston Scientific is the larger business by last-quarter revenue ($5.2B vs $4.5B, roughly 1.1× PILGRIMS PRIDE CORP). Boston Scientific runs the higher net margin — 25.7% vs 2.2%, a 23.5% gap on every dollar of revenue. On growth, Boston Scientific posted the faster year-over-year revenue change (11.6% vs 1.6%). Over the past eight quarters, Boston Scientific's revenue compounded faster (12.4% CAGR vs -0.3%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Pilgrim's Pride Corporation is an American, multi-national food company, currently one of the largest chicken producers in the United States and Puerto Rico and the second-largest chicken producer in Mexico. It exited bankruptcy in December 2009 and relocated its U.S. headquarters to Greeley, Colorado, in 2011. It is majority-owned by JBS S.A. Pilgrim's Pride purchased Gold'n Plump for $350 million in late November 2016.
BSX vs PPC — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $4.5B |
| Net Profit | $1.3B | $101.5M |
| Gross Margin | 69.5% | 7.6% |
| Operating Margin | — | 3.6% |
| Net Margin | 25.7% | 2.2% |
| Revenue YoY | 11.6% | 1.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.90 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | $4.5B | ||
| Q4 25 | $5.3B | $4.5B | ||
| Q3 25 | $5.1B | $4.8B | ||
| Q2 25 | $5.1B | $4.8B | ||
| Q1 25 | $4.7B | $4.5B | ||
| Q4 24 | $4.6B | $4.4B | ||
| Q3 24 | $4.2B | $4.6B | ||
| Q2 24 | $4.1B | $4.6B |
| Q1 26 | $1.3B | $101.5M | ||
| Q4 25 | $670.0M | $88.0M | ||
| Q3 25 | $755.0M | $342.8M | ||
| Q2 25 | $795.0M | $355.5M | ||
| Q1 25 | $672.0M | $296.0M | ||
| Q4 24 | $563.0M | $235.9M | ||
| Q3 24 | $468.0M | $349.9M | ||
| Q2 24 | $322.0M | $326.3M |
| Q1 26 | 69.5% | 7.6% | ||
| Q4 25 | 69.6% | 9.5% | ||
| Q3 25 | 69.9% | 13.9% | ||
| Q2 25 | 67.7% | 15.0% | ||
| Q1 25 | 68.8% | 12.4% | ||
| Q4 24 | 67.8% | 12.7% | ||
| Q3 24 | 68.8% | 14.9% | ||
| Q2 24 | 69.2% | 15.2% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 15.6% | 4.5% | ||
| Q3 25 | 20.7% | 10.4% | ||
| Q2 25 | 16.2% | 10.8% | ||
| Q1 25 | 19.8% | 9.1% | ||
| Q4 24 | 14.8% | 7.0% | ||
| Q3 24 | 17.4% | 11.1% | ||
| Q2 24 | 12.6% | 9.7% |
| Q1 26 | 25.7% | 2.2% | ||
| Q4 25 | 12.7% | 1.9% | ||
| Q3 25 | 14.9% | 7.2% | ||
| Q2 25 | 15.7% | 7.5% | ||
| Q1 25 | 14.4% | 6.6% | ||
| Q4 24 | 12.3% | 5.4% | ||
| Q3 24 | 11.1% | 7.6% | ||
| Q2 24 | 7.8% | 7.2% |
| Q1 26 | $0.90 | $0.43 | ||
| Q4 25 | $0.45 | $0.37 | ||
| Q3 25 | $0.51 | $1.44 | ||
| Q2 25 | $0.53 | $1.49 | ||
| Q1 25 | $0.45 | $1.24 | ||
| Q4 24 | $0.38 | $1.00 | ||
| Q3 24 | $0.32 | $1.47 | ||
| Q2 24 | $0.22 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $542.4M |
| Total DebtLower is stronger | — | $3.1B |
| Stockholders' EquityBook value | — | $3.7B |
| Total Assets | — | $10.2B |
| Debt / EquityLower = less leverage | — | 0.83× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $542.4M | ||
| Q4 25 | $2.0B | $640.2M | ||
| Q3 25 | $1.3B | $612.6M | ||
| Q2 25 | $534.0M | $849.0M | ||
| Q1 25 | $725.0M | $2.1B | ||
| Q4 24 | $414.0M | $2.0B | ||
| Q3 24 | $2.5B | $1.9B | ||
| Q2 24 | $2.9B | $1.3B |
| Q1 26 | — | $3.1B | ||
| Q4 25 | $11.1B | $3.1B | ||
| Q3 25 | $11.1B | $3.1B | ||
| Q2 25 | $11.1B | $3.1B | ||
| Q1 25 | $10.5B | $3.2B | ||
| Q4 24 | $9.0B | $3.2B | ||
| Q3 24 | $9.2B | $3.2B | ||
| Q2 24 | $9.0B | $3.2B |
| Q1 26 | — | $3.7B | ||
| Q4 25 | $24.2B | $3.7B | ||
| Q3 25 | $23.4B | $3.5B | ||
| Q2 25 | $22.4B | $3.7B | ||
| Q1 25 | $22.2B | $3.1B | ||
| Q4 24 | $21.8B | $4.2B | ||
| Q3 24 | $20.7B | $4.2B | ||
| Q2 24 | $20.4B | $3.7B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $43.7B | $10.3B | ||
| Q3 25 | $42.7B | $10.0B | ||
| Q2 25 | $41.6B | $10.1B | ||
| Q1 25 | $40.1B | $11.0B | ||
| Q4 24 | $39.4B | $10.7B | ||
| Q3 24 | $38.1B | $10.7B | ||
| Q2 24 | $37.1B | $10.1B |
| Q1 26 | — | 0.83× | ||
| Q4 25 | 0.46× | 0.84× | ||
| Q3 25 | 0.48× | 0.87× | ||
| Q2 25 | 0.50× | 0.83× | ||
| Q1 25 | 0.47× | 1.02× | ||
| Q4 24 | 0.41× | 0.76× | ||
| Q3 24 | 0.45× | 0.76× | ||
| Q2 24 | 0.44× | 0.85× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| MedSurg | $1.7B | 33% |
| EMEA | $932.0M | 18% |
| APAC | $803.0M | 15% |
| Endoscopy | $736.0M | 14% |
| Urology | $646.0M | 12% |
| Neuromodulation | $318.0M | 6% |
PPC
| U.S | $2.6B | 58% |
| Europe | $1.4B | 30% |
| Mexico | $545.5M | 12% |
